| | | Orphan drug program continues to yield treatments for serious conditions
July 3, 2008
The US orphan drug program has demonstrated that economic incentives and regulatory flexibility can spur development of treatments for small patient populations. Since enactment of the Orphan Drug Act (ODA) in 1983, FDA has approved >300 medicines for approximately 12 million patients around the world. However, there are approximately 6,000 to 8,000 rare diseases, so “we still have a very long way to go,” commented Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER), at a May conference commemorating ODA’s 25th anniversary, which was sponsored by the Drug Information Association (DIA). | |
|  More Articles |
| | |
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.